How Analysts Feel About Bristol-Myers Squibb Company (BMY)?

0
7

As of Wednesday close, Bristol-Myers Squibb Company’s (NYSE:BMY) stock was up $0.28, moving up 0.36 percent to $79.14. The average number of shares traded per day over the past five days has been 7,687,640 shares. 4 times new highs have been achieved over the past 5 days, with a $2.99 gain in that time frame. In the last twenty days, the average volume was 9,730,570, while in the previous 50 days, it was 9,531,481.

Since last month, BMY stock rose 8.75%. Shares of the company fell to $72.25 on 10/25/22, the lowest level in the past month. A 52-week high of $81.17 was reached on 11/09/22 after having rallying from a 52-week low of $53.22. Since the beginning of this year, BMY’s stock price has risen by 26.93% or $16.79, and marked a new high 34 times. However, the stock has declined by -2.50% since its 52-week high.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 16 days ago on Nov 09. Powell Ann, the EVP, Chief Human Resources of the company, disposed of 16,250 shares for $80.45 on Nov 09. It resulted in a $1,307,312 divestment by the insider. VESSEY RUPERT sold 45,910 shares at an average price of $78.88 on Nov 07. The insider now owns 57,079 shares following the transaction. On Sep 20, Board Chair and CEO Caforio Giovanni sold 25,000 shares at $69.71 apiece. The transaction was valued at $1,742,750.

Valuation Metrics

Right now, Bristol-Myers Squibb Company (BMY) has a P/E ratio of about 25.80. The stock’s beta is 0.39. Besides these, the trailing price-to-sales (P/S) ratio of 3.59, the price-to-book (PB) ratio of 5.17, and the price-to-cash flow ratio of 20.60 may also be considered.

The latest dividend of $0.54 per share was paid out, remained unchanged from last year’s $0.54. On Monday December 13 2021, a $0.05 dividend increase was announced.

Financial Health

In the three months ended September 29, Bristol-Myers Squibb Company’s quick ratio stood at 1.30, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.13, and the total debt-to-equity ratio was 1.20. On the profitability front, the trailing twelve-month gross margin is 78.90% percent. In the year ended September 29, operating margins totaled 22.20%. Based on annual data, BMY earned $36.45 billion in gross profit and brought in $46.38 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 9.40%. Return on equity (ROE) for the past 12 months was 20.10%.

In Bristol-Myers Squibb Company’s quarter-end financial report for September 29, it reported total debt of $36.97 billion against cash and short-term investments of $1.29 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BMY’s revenue fell -3.62% to $11.89 billion during the quarter, while net income inched up to $11.22 billion. While analysts expected Bristol-Myers Squibb Company to report $1.83 quarterly earnings, the actual figure was $1.99 per share, beating the consensus estimate by 8.70%. During the quarter, the company generated $4.8 billion in EBITDA. The liabilities of Bristol-Myers Squibb Company were 65.46 billion at the end of its most recent quarter ended September 29, and its total debt was $43.05 billion. The value of shareholders’ equity is $2.13 billion.

Technical Picture

This quick technical analysis looks at Bristol-Myers Squibb Company’s (BMY) price momentum. With a historical volatility rate of 26.72%, the RSI 9-day stood at 66.56% on 23 November.

With respect to its five-day moving average, the current Bristol-Myers Squibb Company price is up by +3.93% percent or $2.99. At present, BMY shares trade +6.30% above its 20-day simple moving average and +4.19% percent above its 100-day simple moving average. However, the stock is currently trading approximately +12.30% above its SMA50 and +20.11% above its SMA200.

Stochastic coefficient K was 67.00% and Stochastic coefficient D was 58.47%, while ATR was 1.58. Given the Stochastic reading of 69.32% for the 14-day period, the RSI (14) reading has been calculated as 64.76%. As of today, the MACD Oscillator reading stands at 1.61, while the 14-day reading stands at 0.88.

Analyst Ratings

Credit Suisse launched its rating on Bristol-Myers Squibb Company (NYSE: BMY) to a Neutral in a note to investors on November 18, 2022. Bristol-Myers Squibb Company (BMY) has been rated Overweight by analysts. According to 1 brokerage firm, BMY is a sell, and 11 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Bristol-Myers Squibb Company stock as buy, with 9 recommending it as overweight.

With a median target price of $83.00, the current consensus forecast for the stock is $60.00 – $90.00. Based on these forecasts, analysts predict Bristol-Myers Squibb Company (BMY) will achieve an average price target of $80.33.

LEAVE A REPLY

Please enter your comment!
Please enter your name here